Ceftriaxone (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Ceftriaxone" in English language version.

refsWebsite

Global rank English rank

36nih.gov

4^th place

23doi.org

2^nd place

18web.archive.org

1^st place

8semanticscholar.org

11^th place

8^th place

2drugs.com

399^th place

333^rd place

2books.google.com

3^rd place

2harvard.edu

18^th place

17^th place

2aap.org

low place

1tga.gov.au

3,984^th place

2,622^nd place

1handle.net

102^nd place

76^th place

1worldcat.org

5^th place

1gov.uk

432^nd place

278^th place

1fda.gov

447^th place

338^th place

1medscape.com

719^th place

636^th place

1utah.edu

2,446^th place

1,661^st place

1alsconsortium.org

low place

aap.org

publications.aap.org

Li N, Zhou X, Yuan J, Chen G, Jiang H, Zhang W (April 2014). "Ceftriaxone and acute renal failure in children" (PDF). Pediatrics. 133 (4): e917–e922. doi:10.1542/peds.2013-2103. PMID 24664092. S2CID 2854637. Archived (PDF) from the original on 22 February 2024. Retrieved 22 February 2024.
Bradley JS, Wassel RT, Lee L, Nambiar S (April 2009). "Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events" (PDF). Pediatrics. 123 (4): e609–e613. doi:10.1542/peds.2008-3080. PMID 19289450. S2CID 22718923. Archived (PDF) from the original on 22 February 2024. Retrieved 22 February 2024.

alsconsortium.org

"Statement on the Clinical Trial of Ceftriaxone". The Northeast ALS Consortium (NEALS). 8 August 2012. Archived from the original on 28 May 2013. Retrieved 10 May 2013.

books.google.com

Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 495. ISBN 978-3-527-60749-5.
Nursing Pharmacology Made Incredibly Easy!. Lippincott Williams & Wilkins. 7 March 2012. p. 496. ISBN 978-1-4511-4624-0. Archived from the original on 3 June 2016.

doi.org

Beam TR (1985). "Ceftriaxone: a beta-lactamase-stable, broad-spectrum cephalosporin with an extended half-life". Pharmacotherapy. 5 (5): 237–253. doi:10.1002/j.1875-9114.1985.tb03423.x. PMID 3906584. S2CID 25559476.
St Cyr S, Barbee L, Workowski KA, Bachmann LH, Pham C, Schlanger K, et al. (December 2020). "Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020". MMWR. Morbidity and Mortality Weekly Report. 69 (50): 1911–1916. doi:10.15585/mmwr.mm6950a6. PMC 7745960. PMID 33332296.
Di Bella S, Gatti M, Principe L (29 April 2023). "Ceftriaxone for methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia: a matter of dosages?". European Journal of Clinical Microbiology & Infectious Diseases. 42 (7): 917–918. doi:10.1007/s10096-023-04612-x. ISSN 1435-4373. PMID 37119346. S2CID 258423746.
Palzkill T (January 2013). "Metallo-β-lactamase structure and function". Ann N Y Acad Sci. 1277 (1): 91–104. Bibcode:2013NYASA1277...91P. doi:10.1111/j.1749-6632.2012.06796.x. PMC 3970115. PMID 23163348.
Shiffman ML, Keith FB, Moore EW (December 1990). "Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility". Gastroenterology. 99 (6): 1772–1778. doi:10.1016/0016-5085(90)90486-K. PMID 2227290.
Shrimali JD, Patel HV, Gumber MR, Kute VB, Shah PR, Vanikar AV, et al. (November 2013). "Ceftriaxone induced immune hemolytic anemia with disseminated intravascular coagulation". Indian Journal of Critical Care Medicine. 17 (6): 394–395. doi:10.4103/0972-5229.123465. PMC 3902580. PMID 24501497.
Guleria VS, Sharma N, Amitabh S, Nair V (September–October 2013). "Ceftriaxone-induced hemolysis". Indian Journal of Pharmacology. 45 (5): 530–531. doi:10.4103/0253-7613.117758. PMC 3793531. PMID 24130395.
Li N, Zhou X, Yuan J, Chen G, Jiang H, Zhang W (April 2014). "Ceftriaxone and acute renal failure in children" (PDF). Pediatrics. 133 (4): e917–e922. doi:10.1542/peds.2013-2103. PMID 24664092. S2CID 2854637. Archived (PDF) from the original on 22 February 2024. Retrieved 22 February 2024.
Patel KB, Nicolau DP, Nightingale CH, Quintiliani R (May 1995). "Pharmacokinetics of cefotaxime in healthy volunteers and patients". Diagnostic Microbiology and Infectious Disease. 22 (1–2): 49–55. doi:10.1016/0732-8893(95)00072-I. PMID 7587050.
Bradley JS, Wassel RT, Lee L, Nambiar S (April 2009). "Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events" (PDF). Pediatrics. 123 (4): e609–e613. doi:10.1542/peds.2008-3080. PMID 19289450. S2CID 22718923. Archived (PDF) from the original on 22 February 2024. Retrieved 22 February 2024.
van Heijenoort J (March 2001). "Formation of the glycan chains in the synthesis of bacterial peptidoglycan". Glycobiology. 11 (3): 25R–36R. doi:10.1093/glycob/11.3.25r. PMID 11320055. S2CID 46066256.
Scheffers DJ, Pinho MG (December 2005). "Bacterial cell wall synthesis: new insights from localization studies". Microbiology and Molecular Biology Reviews. 69 (4): 585–607. doi:10.1128/MMBR.69.4.585-607.2005. PMC 1306805. PMID 16339737.
Nau R, Sörgel F, Eiffert H (October 2010). "Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections". Clinical Microbiology Reviews. 23 (4): 858–883. doi:10.1128/CMR.00007-10. PMC 2952976. PMID 20930076.
Arvidsson A, Alván G, Angelin B, Borgå O, Nord CE (September 1982). "Ceftriaxone: renal and biliary excretion and effect on the colon microflora". The Journal of Antimicrobial Chemotherapy. 10 (3): 207–215. doi:10.1093/jac/10.3.207. PMID 6292158.
Blumer J (September 1991). "Pharmacokinetics of ceftriaxone". Hospital Practice. 26 (Suppl 5): 7–13, discussion 52–4. doi:10.1080/21548331.1991.11707737. PMID 1918224.
Balant L, Dayer P, Auckenthaler R (1 April 1985). "Clinical pharmacokinetics of the third generation cephalosporins". Clinical Pharmacokinetics. 10 (2): 101–143. doi:10.2165/00003088-198510020-00001. PMID 3888488. S2CID 23478077.
Klein NC, Cunha BA (July 1995). "Third-generation cephalosporins". The Medical Clinics of North America. 79 (4): 705–719. doi:10.1016/s0025-7125(16)30034-7. PMID 7791418.
Schichor A, Bernstein B, Weinerman H, Fitzgerald J, Yordan E, Schechter N (January 1994). "Lidocaine as a diluent for ceftriaxone in the treatment of gonorrhea. Does it reduce the pain of the injection?". Archives of Pediatrics & Adolescent Medicine. 148 (1): 72–75. doi:10.1001/archpedi.1994.02170010074017. PMID 8143016.
Knackstedt LA, Melendez RI, Kalivas PW (January 2010). "Ceftriaxone restores glutamate homeostasis and prevents relapse to cocaine seeking". Biological Psychiatry. 67 (1): 81–84. doi:10.1016/j.biopsych.2009.07.018. PMC 2795043. PMID 19717140.
Verma R, Mishra V, Sasmal D, Raghubir R (July 2010). "Pharmacological evaluation of glutamate transporter 1 (GLT-1) mediated neuroprotection following cerebral ischemia/reperfusion injury". European Journal of Pharmacology. 638 (1–3): 65–71. doi:10.1016/j.ejphar.2010.04.021. PMID 20423712.
Lee SG, Su ZZ, Emdad L, Gupta P, Sarkar D, Borjabad A, et al. (May 2008). "Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression and glutamate uptake in primary human astrocytes". The Journal of Biological Chemistry. 283 (19): 13116–13123. doi:10.1074/jbc.M707697200. PMC 2442320. PMID 18326497.
Hedlund E (September 2011). "The protective effects of β-lactam antibiotics in motor neuron disorders". Experimental Neurology. 231 (1): 14–18. doi:10.1016/j.expneurol.2011.06.002. PMID 21693120. S2CID 26353910.
Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, et al. (January 2005). "Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression". Nature. 433 (7021): 73–77. Bibcode:2005Natur.433...73R. doi:10.1038/nature03180. PMID 15635412. S2CID 4301666.

drugs.com

"Ceftriaxone (Rocephin) Use During Pregnancy". Drugs.com. 12 December 2019. Archived from the original on 23 August 2016. Retrieved 24 December 2019.
"Ceftriaxone Sodium Monograph for Professionals". Drugs.com. Archived from the original on 31 May 2016. Retrieved 27 August 2016.

fda.gov

accessdata.fda.gov

"Rocephin Prescribing Information" (PDF). Roche. Archived (PDF) from the original on 4 March 2016. Retrieved 1 November 2015.

gov.uk

"Ceftriaxone (Rocephin): Incompatible with solutions containing calcium". Archived from the original on 8 December 2023.

handle.net

hdl.handle.net

World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

harvard.edu

ui.adsabs.harvard.edu

Palzkill T (January 2013). "Metallo-β-lactamase structure and function". Ann N Y Acad Sci. 1277 (1): 91–104. Bibcode:2013NYASA1277...91P. doi:10.1111/j.1749-6632.2012.06796.x. PMC 3970115. PMID 23163348.
Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, et al. (January 2005). "Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression". Nature. 433 (7021): 73–77. Bibcode:2005Natur.433...73R. doi:10.1038/nature03180. PMID 15635412. S2CID 4301666.

medscape.com

"The Use of Cephalosporins in Penicillin-allergic Patients". www.medscape.com. Archived from the original on 14 November 2015. Retrieved 10 November 2015.

nih.gov

pubmed.ncbi.nlm.nih.gov

Beam TR (1985). "Ceftriaxone: a beta-lactamase-stable, broad-spectrum cephalosporin with an extended half-life". Pharmacotherapy. 5 (5): 237–253. doi:10.1002/j.1875-9114.1985.tb03423.x. PMID 3906584. S2CID 25559476.
St Cyr S, Barbee L, Workowski KA, Bachmann LH, Pham C, Schlanger K, et al. (December 2020). "Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020". MMWR. Morbidity and Mortality Weekly Report. 69 (50): 1911–1916. doi:10.15585/mmwr.mm6950a6. PMC 7745960. PMID 33332296.
Di Bella S, Gatti M, Principe L (29 April 2023). "Ceftriaxone for methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia: a matter of dosages?". European Journal of Clinical Microbiology & Infectious Diseases. 42 (7): 917–918. doi:10.1007/s10096-023-04612-x. ISSN 1435-4373. PMID 37119346. S2CID 258423746.
Palzkill T (January 2013). "Metallo-β-lactamase structure and function". Ann N Y Acad Sci. 1277 (1): 91–104. Bibcode:2013NYASA1277...91P. doi:10.1111/j.1749-6632.2012.06796.x. PMC 3970115. PMID 23163348.
Shiffman ML, Keith FB, Moore EW (December 1990). "Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility". Gastroenterology. 99 (6): 1772–1778. doi:10.1016/0016-5085(90)90486-K. PMID 2227290.
Shrimali JD, Patel HV, Gumber MR, Kute VB, Shah PR, Vanikar AV, et al. (November 2013). "Ceftriaxone induced immune hemolytic anemia with disseminated intravascular coagulation". Indian Journal of Critical Care Medicine. 17 (6): 394–395. doi:10.4103/0972-5229.123465. PMC 3902580. PMID 24501497.
Guleria VS, Sharma N, Amitabh S, Nair V (September–October 2013). "Ceftriaxone-induced hemolysis". Indian Journal of Pharmacology. 45 (5): 530–531. doi:10.4103/0253-7613.117758. PMC 3793531. PMID 24130395.
Li N, Zhou X, Yuan J, Chen G, Jiang H, Zhang W (April 2014). "Ceftriaxone and acute renal failure in children" (PDF). Pediatrics. 133 (4): e917–e922. doi:10.1542/peds.2013-2103. PMID 24664092. S2CID 2854637. Archived (PDF) from the original on 22 February 2024. Retrieved 22 February 2024.
Patel KB, Nicolau DP, Nightingale CH, Quintiliani R (May 1995). "Pharmacokinetics of cefotaxime in healthy volunteers and patients". Diagnostic Microbiology and Infectious Disease. 22 (1–2): 49–55. doi:10.1016/0732-8893(95)00072-I. PMID 7587050.
Guggenbichler JP, Allerberger FJ, Dierich M (1986). "Influence of cephalosporines III generation with varying biliary excretion on fecal flora and emergence of resistant bacteria during and after cessation of therapy". Padiatrie und Padologie. 21 (4): 335–342. PMID 3562044. Archived from the original on 29 April 2023. Retrieved 29 April 2023.
Bradley JS, Wassel RT, Lee L, Nambiar S (April 2009). "Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events" (PDF). Pediatrics. 123 (4): e609–e613. doi:10.1542/peds.2008-3080. PMID 19289450. S2CID 22718923. Archived (PDF) from the original on 22 February 2024. Retrieved 22 February 2024.
van Heijenoort J (March 2001). "Formation of the glycan chains in the synthesis of bacterial peptidoglycan". Glycobiology. 11 (3): 25R–36R. doi:10.1093/glycob/11.3.25r. PMID 11320055. S2CID 46066256.
Scheffers DJ, Pinho MG (December 2005). "Bacterial cell wall synthesis: new insights from localization studies". Microbiology and Molecular Biology Reviews. 69 (4): 585–607. doi:10.1128/MMBR.69.4.585-607.2005. PMC 1306805. PMID 16339737.
Patel IH, Kaplan SA (October 1984). "Pharmacokinetic profile of ceftriaxone in man". The American Journal of Medicine. 77 (4C): 17–25. PMID 6093513.
Nau R, Sörgel F, Eiffert H (October 2010). "Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections". Clinical Microbiology Reviews. 23 (4): 858–883. doi:10.1128/CMR.00007-10. PMC 2952976. PMID 20930076.
Arvidsson A, Alván G, Angelin B, Borgå O, Nord CE (September 1982). "Ceftriaxone: renal and biliary excretion and effect on the colon microflora". The Journal of Antimicrobial Chemotherapy. 10 (3): 207–215. doi:10.1093/jac/10.3.207. PMID 6292158.
Blumer J (September 1991). "Pharmacokinetics of ceftriaxone". Hospital Practice. 26 (Suppl 5): 7–13, discussion 52–4. doi:10.1080/21548331.1991.11707737. PMID 1918224.
Balant L, Dayer P, Auckenthaler R (1 April 1985). "Clinical pharmacokinetics of the third generation cephalosporins". Clinical Pharmacokinetics. 10 (2): 101–143. doi:10.2165/00003088-198510020-00001. PMID 3888488. S2CID 23478077.
Klein NC, Cunha BA (July 1995). "Third-generation cephalosporins". The Medical Clinics of North America. 79 (4): 705–719. doi:10.1016/s0025-7125(16)30034-7. PMID 7791418.
Schichor A, Bernstein B, Weinerman H, Fitzgerald J, Yordan E, Schechter N (January 1994). "Lidocaine as a diluent for ceftriaxone in the treatment of gonorrhea. Does it reduce the pain of the injection?". Archives of Pediatrics & Adolescent Medicine. 148 (1): 72–75. doi:10.1001/archpedi.1994.02170010074017. PMID 8143016.
Knackstedt LA, Melendez RI, Kalivas PW (January 2010). "Ceftriaxone restores glutamate homeostasis and prevents relapse to cocaine seeking". Biological Psychiatry. 67 (1): 81–84. doi:10.1016/j.biopsych.2009.07.018. PMC 2795043. PMID 19717140.
Verma R, Mishra V, Sasmal D, Raghubir R (July 2010). "Pharmacological evaluation of glutamate transporter 1 (GLT-1) mediated neuroprotection following cerebral ischemia/reperfusion injury". European Journal of Pharmacology. 638 (1–3): 65–71. doi:10.1016/j.ejphar.2010.04.021. PMID 20423712.
Lee SG, Su ZZ, Emdad L, Gupta P, Sarkar D, Borjabad A, et al. (May 2008). "Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression and glutamate uptake in primary human astrocytes". The Journal of Biological Chemistry. 283 (19): 13116–13123. doi:10.1074/jbc.M707697200. PMC 2442320. PMID 18326497.
Hedlund E (September 2011). "The protective effects of β-lactam antibiotics in motor neuron disorders". Experimental Neurology. 231 (1): 14–18. doi:10.1016/j.expneurol.2011.06.002. PMID 21693120. S2CID 26353910.
Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, et al. (January 2005). "Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression". Nature. 433 (7021): 73–77. Bibcode:2005Natur.433...73R. doi:10.1038/nature03180. PMID 15635412. S2CID 4301666.

ncbi.nlm.nih.gov

St Cyr S, Barbee L, Workowski KA, Bachmann LH, Pham C, Schlanger K, et al. (December 2020). "Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020". MMWR. Morbidity and Mortality Weekly Report. 69 (50): 1911–1916. doi:10.15585/mmwr.mm6950a6. PMC 7745960. PMID 33332296.
Palzkill T (January 2013). "Metallo-β-lactamase structure and function". Ann N Y Acad Sci. 1277 (1): 91–104. Bibcode:2013NYASA1277...91P. doi:10.1111/j.1749-6632.2012.06796.x. PMC 3970115. PMID 23163348.
Shrimali JD, Patel HV, Gumber MR, Kute VB, Shah PR, Vanikar AV, et al. (November 2013). "Ceftriaxone induced immune hemolytic anemia with disseminated intravascular coagulation". Indian Journal of Critical Care Medicine. 17 (6): 394–395. doi:10.4103/0972-5229.123465. PMC 3902580. PMID 24501497.
Guleria VS, Sharma N, Amitabh S, Nair V (September–October 2013). "Ceftriaxone-induced hemolysis". Indian Journal of Pharmacology. 45 (5): 530–531. doi:10.4103/0253-7613.117758. PMC 3793531. PMID 24130395.
Scheffers DJ, Pinho MG (December 2005). "Bacterial cell wall synthesis: new insights from localization studies". Microbiology and Molecular Biology Reviews. 69 (4): 585–607. doi:10.1128/MMBR.69.4.585-607.2005. PMC 1306805. PMID 16339737.
Nau R, Sörgel F, Eiffert H (October 2010). "Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections". Clinical Microbiology Reviews. 23 (4): 858–883. doi:10.1128/CMR.00007-10. PMC 2952976. PMID 20930076.
Knackstedt LA, Melendez RI, Kalivas PW (January 2010). "Ceftriaxone restores glutamate homeostasis and prevents relapse to cocaine seeking". Biological Psychiatry. 67 (1): 81–84. doi:10.1016/j.biopsych.2009.07.018. PMC 2795043. PMID 19717140.
Lee SG, Su ZZ, Emdad L, Gupta P, Sarkar D, Borjabad A, et al. (May 2008). "Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression and glutamate uptake in primary human astrocytes". The Journal of Biological Chemistry. 283 (19): 13116–13123. doi:10.1074/jbc.M707697200. PMC 2442320. PMID 18326497.

dailymed.nlm.nih.gov

"Ceftriaxone- ceftriaxone sodium injection, powder, for solution". DailyMed. 31 December 2019. Archived from the original on 17 November 2015. Retrieved 1 February 2020.
"DailyMed – Search Results for ceftriaxone". dailymed.nlm.nih.gov. Archived from the original on 6 March 2016. Retrieved 4 November 2015.

toxnet.nlm.nih.gov

"TOXNET". toxnet.nlm.nih.gov. Archived from the original on 8 September 2017. Retrieved 4 November 2015.

semanticscholar.org

api.semanticscholar.org

Beam TR (1985). "Ceftriaxone: a beta-lactamase-stable, broad-spectrum cephalosporin with an extended half-life". Pharmacotherapy. 5 (5): 237–253. doi:10.1002/j.1875-9114.1985.tb03423.x. PMID 3906584. S2CID 25559476.
Di Bella S, Gatti M, Principe L (29 April 2023). "Ceftriaxone for methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia: a matter of dosages?". European Journal of Clinical Microbiology & Infectious Diseases. 42 (7): 917–918. doi:10.1007/s10096-023-04612-x. ISSN 1435-4373. PMID 37119346. S2CID 258423746.
Li N, Zhou X, Yuan J, Chen G, Jiang H, Zhang W (April 2014). "Ceftriaxone and acute renal failure in children" (PDF). Pediatrics. 133 (4): e917–e922. doi:10.1542/peds.2013-2103. PMID 24664092. S2CID 2854637. Archived (PDF) from the original on 22 February 2024. Retrieved 22 February 2024.
Bradley JS, Wassel RT, Lee L, Nambiar S (April 2009). "Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events" (PDF). Pediatrics. 123 (4): e609–e613. doi:10.1542/peds.2008-3080. PMID 19289450. S2CID 22718923. Archived (PDF) from the original on 22 February 2024. Retrieved 22 February 2024.
van Heijenoort J (March 2001). "Formation of the glycan chains in the synthesis of bacterial peptidoglycan". Glycobiology. 11 (3): 25R–36R. doi:10.1093/glycob/11.3.25r. PMID 11320055. S2CID 46066256.
Balant L, Dayer P, Auckenthaler R (1 April 1985). "Clinical pharmacokinetics of the third generation cephalosporins". Clinical Pharmacokinetics. 10 (2): 101–143. doi:10.2165/00003088-198510020-00001. PMID 3888488. S2CID 23478077.
Hedlund E (September 2011). "The protective effects of β-lactam antibiotics in motor neuron disorders". Experimental Neurology. 231 (1): 14–18. doi:10.1016/j.expneurol.2011.06.002. PMID 21693120. S2CID 26353910.
Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, et al. (January 2005). "Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression". Nature. 433 (7021): 73–77. Bibcode:2005Natur.433...73R. doi:10.1038/nature03180. PMID 15635412. S2CID 4301666.

tga.gov.au

"Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 6 July 2023. Retrieved 30 March 2024.

utah.edu

healthcare.utah.edu

"FDA Updates warning on Ceftriaxone-Calcium injection". Archived from the original on 28 November 2009.

web.archive.org

"Ceftriaxone (Rocephin) Use During Pregnancy". Drugs.com. 12 December 2019. Archived from the original on 23 August 2016. Retrieved 24 December 2019.
"Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 6 July 2023. Retrieved 30 March 2024.
"Ceftriaxone Sodium Monograph for Professionals". Drugs.com. Archived from the original on 31 May 2016. Retrieved 27 August 2016.
"Ceftriaxone- ceftriaxone sodium injection, powder, for solution". DailyMed. 31 December 2019. Archived from the original on 17 November 2015. Retrieved 1 February 2020.
https://web.archive.org/web/20231206072711/https://www.medsafe.govt.nz/profs/datasheet/c/ceftriaxoneinjDEVA.pdf ^{[bare URL PDF]}
https://web.archive.org/web/20230813180009/https://www.pbm.va.gov/PBM/vacenterformedicationsafety/nationalpbmbulletin/CeftriaxoneNationalPBMBulletin.pdf ^{[bare URL PDF]}
"Ceftriaxone (Rocephin): Incompatible with solutions containing calcium". Archived from the original on 8 December 2023.
https://web.archive.org/web/20240222194630/https://www.hpra.ie/docs/default-source/Safety-Notices/ceftriaxone---march-2010---final.pdf ^{[bare URL PDF]}
"TOXNET". toxnet.nlm.nih.gov. Archived from the original on 8 September 2017. Retrieved 4 November 2015.
"Rocephin Prescribing Information" (PDF). Roche. Archived (PDF) from the original on 4 March 2016. Retrieved 1 November 2015.
Li N, Zhou X, Yuan J, Chen G, Jiang H, Zhang W (April 2014). "Ceftriaxone and acute renal failure in children" (PDF). Pediatrics. 133 (4): e917–e922. doi:10.1542/peds.2013-2103. PMID 24664092. S2CID 2854637. Archived (PDF) from the original on 22 February 2024. Retrieved 22 February 2024.
Guggenbichler JP, Allerberger FJ, Dierich M (1986). "Influence of cephalosporines III generation with varying biliary excretion on fecal flora and emergence of resistant bacteria during and after cessation of therapy". Padiatrie und Padologie. 21 (4): 335–342. PMID 3562044. Archived from the original on 29 April 2023. Retrieved 29 April 2023.
"The Use of Cephalosporins in Penicillin-allergic Patients". www.medscape.com. Archived from the original on 14 November 2015. Retrieved 10 November 2015.
"FDA Updates warning on Ceftriaxone-Calcium injection". Archived from the original on 28 November 2009.
Bradley JS, Wassel RT, Lee L, Nambiar S (April 2009). "Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events" (PDF). Pediatrics. 123 (4): e609–e613. doi:10.1542/peds.2008-3080. PMID 19289450. S2CID 22718923. Archived (PDF) from the original on 22 February 2024. Retrieved 22 February 2024.
"DailyMed – Search Results for ceftriaxone". dailymed.nlm.nih.gov. Archived from the original on 6 March 2016. Retrieved 4 November 2015.
Nursing Pharmacology Made Incredibly Easy!. Lippincott Williams & Wilkins. 7 March 2012. p. 496. ISBN 978-1-4511-4624-0. Archived from the original on 3 June 2016.
"Statement on the Clinical Trial of Ceftriaxone". The Northeast ALS Consortium (NEALS). 8 August 2012. Archived from the original on 28 May 2013. Retrieved 10 May 2013.

worldcat.org

search.worldcat.org

Di Bella S, Gatti M, Principe L (29 April 2023). "Ceftriaxone for methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia: a matter of dosages?". European Journal of Clinical Microbiology & Infectious Diseases. 42 (7): 917–918. doi:10.1007/s10096-023-04612-x. ISSN 1435-4373. PMID 37119346. S2CID 258423746.